Immunocore Total Stockholder Equity from 2010 to 2024
| IMCR Stock | USD 32.83 0.38 1.17% |
Total Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 368.8 M | Current Value 387.3 M | Quarterly Volatility 123.2 M |
Check Immunocore Holdings financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunocore Holdings' main balance sheet or income statement drivers, such as Interest Expense of 3.6 M, Other Operating Expenses of 324.5 M or Tax Provision of 2.5 M, as well as many indicators such as Price To Sales Ratio of 12.72, Dividend Yield of 0.0 or PTB Ratio of 8.6. Immunocore financial statements analysis is a perfect complement when working with Immunocore Holdings Valuation or Volatility modules.
Immunocore | Total Stockholder Equity |
Latest Immunocore Holdings' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Immunocore Holdings over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Immunocore Holdings' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunocore Holdings' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Immunocore Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 119,052,410 | |
| Geometric Mean | 79,690,283 | |
| Coefficient Of Variation | 103.52 | |
| Mean Deviation | 97,362,868 | |
| Median | 56,582,000 | |
| Standard Deviation | 123,248,051 | |
| Sample Variance | 15190.1T | |
| Range | 372.5M | |
| R-Value | 0.74 | |
| Mean Square Error | 7520.6T | |
| R-Squared | 0.54 | |
| Significance | 0 | |
| Slope | 20,256,743 | |
| Total Sum of Squares | 212661.1T |
Immunocore Total Stockholder Equity History
About Immunocore Holdings Financial Statements
Immunocore Holdings shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Immunocore Holdings investors may analyze each financial statement separately, they are all interrelated. The changes in Immunocore Holdings' assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunocore Holdings' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 368.8 M | 387.3 M |
Pair Trading with Immunocore Holdings
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immunocore Holdings position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immunocore Holdings will appreciate offsetting losses from the drop in the long position's value.Moving against Immunocore Stock
| 0.46 | BHC | Bausch Health Companies | PairCorr |
| 0.35 | HCM | HUTCHMED DRC | PairCorr |
| 0.32 | EWTX | Edgewise Therapeutics | PairCorr |
The ability to find closely correlated positions to Immunocore Holdings could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Immunocore Holdings when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Immunocore Holdings - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Immunocore Holdings to buy it.
The correlation of Immunocore Holdings is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Immunocore Holdings moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Immunocore Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Immunocore Holdings can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Immunocore Stock Analysis
When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.